Description: UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Home Page: www.urogen.com
400 Alexander Park Drive
Princeton,
NJ
08540
United States
Phone:
(646) 768-9780
Officers
| Name | Title |
|---|---|
| Ms. Elizabeth A. Barrett | President, CEO & Director |
| Mr. Jason Drew Smith | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
| Mr. Dong Kim | Chief Financial Officer |
| Vincent I. Perrone | Senior Director of Investor Relations |
| Mr. Bryon Wornson | Executive Vice President of Talent, Advocacy & Communications |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations |
| Mr. James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality |
| Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. | Chief Business Officer |
| Mr. Michael J. Louie M.D., M.P.H., M.Sc. | Senior Vice President of Medical Affairs & Clinical Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.5378 |
| Price-to-Sales TTM: | 5.3124 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 204 |